



Pain and Cannabinoid Medicine Update

December 10, 2020

Disclosure Statements

In accordance with the Accreditation Council for Continuing Medical Education's Standards for Commercial Support, The George Washington University Office of CEHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships and that conflicts of interest be identified and resolved prior to the planning and implementation of this activity.

Planning Committee/Faculty: The following speakers and/or planning committee members have indicated they have no relationship(s) with industry to disclose relative to the content of this CME activity:

- **Jeff Bost, PAC**
- **Joseph Maroon, MD**

The following speakers and/or planning committee members have indicated that they have relationship(s) with industry to disclose:

- Faculty member **Wade Cooper, DO** discloses the following relationships: Eli Lilly (Advisory Board and Consulting), Alder (Advisory Board and Consulting), Allergan (Advisory Board and Consulting), Biohaven (Advisory Board and Consulting), Amgen (Advisory Board and Consulting), Dolor (Advisory Board and Consulting), Teva (Advisory Board and Consulting), Theranica (Advisory Board and Consulting).
- Faculty member **Sahar Swidan, PharmD, BCPS, ABAHP, ABAARM** discloses the following relationships: Amgen (Speaker), Biohaven (Speaker)

Disclosures: George Washington University and A4M/MMI staff as well as Activity Planners and reviewers have no relevant financial or non-financial interest to disclose.